Artemisinin Combination Therapy Market Report: Trends, Forecast and Competitive Analysis to 2031
상품코드:1859303
리서치사:Lucintel
발행일:2025년 11월
페이지 정보:영문 150 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
세계 아르테미시닌 병용요법 시장의 미래는 병원, 클리닉 시장에서의 기회로 인해 유망합니다. 세계 아르테미시닌 병용요법 시장은 2025년부터 2031년까지 8.2%의 CAGR로 성장할 것으로 예상됩니다. 이 시장의 주요 촉진요인은 기생충 혈증의 신속한 제거, 증상 완화, 치료 성공률 향상, 약제 내성 말라리아 균주의 출현을 방지하는 데 효과적임이 입증되었다는 점입니다.
Lucintel의 예측에 따르면, 유형별로는 합병증 없는 말라리아 치료에서 우수한 효과와 안전성으로 인해 아르테메테르+루메판트린이 예측 기간 동안 가장 높은 성장세를 보일 것으로 예상됩니다.
용도별로는 특히 말라리아가 유행하는 지역에서는 진료소에서 치료가 보편적으로 이루어지고 있기 때문에 진료소가 높은 성장세를 보일 것으로 예상됩니다.
지역별로는 수입 말라리아 환자 수의 증가와 효과적인 치료 옵션의 필요성 때문에 북미가 예측 기간 동안 가장 큰 지역으로 남을 것으로 보입니다.
아르테미시닌 병용요법 시장의 새로운 동향
아르테미시닌 병용요법 시장은 다양한 기술, 규제, 연구 개발로 인해 빠르게 변화하고 있습니다. 이러한 추세는 약제 내성, 가격 등 말라리아 치료의 진화하는 도전과제를 반영하는 동시에 치료 환경에서의 혁신과 성장의 기회를 강조하고 있습니다. 다음과 같은 새로운 트렌드는 ACT 시장을 재구성하여 보다 효과적이고, 사용하기 쉽고, 지속가능한 솔루션으로 발전시키고 있습니다.
복합제 혁신 : 아르테미시닌 및 기타 항말라리아 복합제(FDC)는 사용 편의성과 환자의 복약 순응도 향상으로 인해 성장세를 보이고 있습니다. FDC는 한 알에 여러 약물을 배합하여 내성 위험을 줄이고 치료 성적을 향상시킵니다. 제약회사는 치료 기간이 짧고 효율이 높은 FDC를 개발하고 있으며, 대규모 말라리아 퇴치 프로그램에 매우 효과적입니다. 이러한 추세는 특히 말라리아 감염이 많은 국가에서 ACTs에 대한 수요를 촉진할 것으로 예상됩니다.
내성 관리에 대한 관심 증가 : 아르테미시닌 기반 치료제에 대한 내성이 우려되면서 연구자들은 이 문제를 극복하기 위한 새로운 약물과 전략 개발에 집중하고 있습니다. 새로운 ACT 조합과 대체 약물을 포함한 내성 관리 노력은 시장에서 중요한 위치를 차지하고 있습니다. 이러한 추세는 특히 동남아시아, 사하라 이남 아프리카 등 약제 내성 말라리아 균주의 영향을 받는 지역에서 ACT 요법의 효과를 유지할 수 있는 혁신적인 약제 개발로 이어지고 있습니다.
민관 파트너십 : 정부, 국제기구, 민간 제약사의 협력은 말라리아 발병 지역에서 ACT에 대한 접근성을 개선하는 데 필수적입니다. 민관협력(PPP)은 저소득 국가에서 ACT를 저렴하게 이용할 수 있도록 하는 열쇠가 될 수 있습니다. 이러한 파트너십을 통해 생산과 유통이 확대되고 새로운 ACT 제제가 개발되고 있습니다. PPP를 통해 이해관계자들은 세계 공급망을 확장하고, 비용을 절감하며, 말라리아가 가장 큰 영향을 미치는 지역에서 ACT 치료제에 대한 접근성을 확대하는 것을 목표로 하고 있습니다.
전달 메커니즘의 발전 : ACT 시장에서는 치료 효과와 환자 순응도 향상을 위한 약물전달 시스템의 발전이 이루어지고 있습니다. 보다 효율적인 투여 요법을 제공하기 위해 방출 조절 제제 및 주사제 ACT와 같은 혁신적인 기술이 조사되고 있습니다. 이러한 추세는 특히 의료 접근성이 제한적이거나 경구 치료가 불가능한 지역에서 ACT의 효과를 높일 수 있을 것으로 기대됩니다. 이러한 기술 혁신은 말라리아 치료 제공에 있어 물류 문제를 해결하는 데 도움이 되고 있습니다.
디지털 헬스 통합 : 모니터링, 진단, 치료 순응도를 향상시키기 위해 디지털 헬스 기술이 말라리아 퇴치 프로그램에 통합되고 있습니다. ACT 치료의 효과를 실시간으로 추적하기 위해 모바일 의료 애플리케이션, 원격의료, 데이터 분석이 점점 더 많이 활용되고 있습니다. 디지털 플랫폼은 환자 교육도 지원하며, 말라리아 예방과 치료에 대한 인식을 높이고 있습니다. 이러한 추세는 ACT 배포 및 모니터링 상황을 변화시키고 있으며, 말라리아에 대한 전 세계 대응을 강화하고 있습니다.
아르테미시닌 병용요법(ACT) 시장은 말라리아 치료 및 통제에 있어 혁신적인 솔루션에 대한 수요 증가를 반영하는 일련의 새로운 트렌드에 의해 형성되고 있습니다. 복합제, 내성 관리 전략, 디지털 헬스 통합과 같은 혁신은 모두 보다 효과적이고 접근성이 높으며 지속가능한 치료 옵션에 기여하고 있습니다. 민관 파트너십과 약물전달 메커니즘의 발전으로 ACT 프로그램의 확장성은 전 세계적으로 더욱 향상되고 있습니다.
아르테미시닌 병용요법 시장의 최근 동향
아르테미시닌 병용요법(ACT) 시장은 말라리아에 대한 전 세계적 대응의 진화를 반영하여 괄목할만한 발전을 거듭하고 있습니다. 이러한 추세는 새로운 치료법의 발전, 국제적인 협력 관계, ACT의 효과, 경제성, 접근성 및 접근성 향상을 위한 규제 업데이트 등의 영향을 받고 있습니다. 아래 주요 발전은 말라리아 치료의 현재와 미래의 과제를 해결하기 위해 ACT 시장이 어떻게 변화하고 있는지를 보여줍니다.
새로운 ACT 제제 도입 : 최근 ACT 시장에서는 아르테미시닌과 피로나리진, 타페노킨과 같은 새로운 파트너를 결합한 새로운 제제의 도입이 활발히 이루어지고 있습니다. 이러한 새로운 조합은 약제 내성과 싸우고 치료 효과를 향상시키기 위해 개발되고 있습니다. 예를 들어, 기존 ACT를 대체하는 피로나리딘 아르테스네이트의 도입은 동남아시아의 아르테미시닌 내성에 대한 우려를 해소할 수 있습니다. 이 새로운 제제는 말라리아 치료에 보다 지속가능한 해결책을 제시할 것으로 기대됩니다.
제네릭 ACT 생산 확대 : 인도, 중국을 비롯한 여러 국가에서 제네릭 ACT 생산이 확대되고 있으며, 이는 말라리아 발병 지역에서 말라리아 치료를 보다 저렴하고 쉽게 이용할 수 있도록 돕고 있습니다. 저소득 국가에서 말라리아 퇴치 프로그램을 성공적으로 수행하기 위해서는 저렴한 제네릭 ACT의 보급이 필수적입니다. 이러한 추세는 특히 정부의 보건 프로그램을 통해 ACTs의 보급에 기여하고 있으며, 말라리아 치료의 경제적 부담을 경감시키고 있습니다.
세계 협력 및 자금 조달 강화 : 세계 에이즈, 결핵, 말라리아 퇴치 기금(GFATM), 세계보건기구(WHO) 등의 세계 협력과 자금 지원으로 전염병이 유행하는 지역에서 ACTs의 접근성이 향상되고 있습니다. 이러한 협력 관계는 ACTs 배포 확대, 의료 인프라 개선, 말라리아 연구에 대한 투자에 초점을 맞추고 있습니다. 사하라 사막 이남 아프리카 및 기타 고부하 지역에서 ACTs의 활용을 확대하기 위해서는 자금 조달 메커니즘과 파트너십 강화가 중요한 역할을 하고 있습니다.
말라리아 퇴치에 집중 : 일부 국가들은 2030년까지 말라리아 퇴치를 약속하고 있으며, ACT는 이러한 국가 전략의 핵심적인 역할을 담당하고 있습니다. 중국과 인도와 같은 국가들은 ACT 공급망을 강화하고, 진단 및 치료율을 개선하고, ACT 사용을 보다 광범위한 공중보건 프로그램에 통합함으로써 말라리아 퇴치를 위한 노력을 기울이고 있습니다. 이러한 노력으로 말라리아 감염률이 낮은 지역과 감염이 지속되고 있는 지역에서의 ACT 보급이 가속화되어 말라리아 감염률을 낮추고, 전 세계 말라리아 퇴치 목표에 가까워지고 있습니다.
ACT 승인에 대한 규제 발전 : 미국 FDA와 유럽의약품청(EMA) 등 규제기관은 최근 새로운 ACT 조합과 제형을 승인했습니다. 이러한 규제 발전으로 ACT의 승인 절차가 간소화되어 혁신적인 치료법에 대한 접근성이 더욱 빨라졌습니다. 새로운 조합과 대체 약물이 승인됨에 따라 ACT 세계 시장은 다양해지고 있으며, 특히 아르테미시닌 내성에 직면한 지역에서는 말라리아 치료 옵션이 확대되고 있습니다.
최근 아르테미시닌 병용요법(ACT) 시장 동향은 약물의 유효성, 접근성 향상, 약제 내성 등의 과제에 대한 대응에 중점을 두고 있습니다. 새로운 제형의 도입, 제네릭 의약품의 증가, 세계 협력 관계로 인해 말라리아가 유행하는 지역에서 ACT의 가용성이 확대되고 있습니다. 말라리아 퇴치를 위한 노력과 규제 당국의 승인 진전이 시장을 재편하는 한편, ACT 제제의 기술 혁신이 치료 결과를 개선하고 있습니다.
목차
제1장 주요 요약
제2장 시장 개요
배경과 분류
공급망
제3장 시장 동향과 예측 분석
업계 성장 촉진요인과 과제
PESTLE 분석
특허 분석
규제 환경
제4장 세계의 아르테미시닌 병용요법 시장 : 종류별
개요
매력 분석 : 종류별
아르테메테르+루메판트린 : 동향과 예측(2019-2031년)
아르테수네이트+아모디아퀸 : 동향과 예측(2019-2031년)
디하이드로아르테미시닌+피페라퀸 : 동향과 예측(2019-2031년)
아르테수네이트+메플로퀸 : 동향과 예측(2019-2031년)
아르테수네이트+설파독신-피리메타민 : 동향과 예측(2019-2031년)
피로나리딘-아르테수네이트 : 동향과 예측(2019-2031년)
기타 : 동향과 예측(2019-2031년)
제5장 세계의 아르테미시닌 병용요법 시장 : 용도별
개요
매력 분석 : 용도별
병원 : 동향과 예측(2019-2031년)
진료소 : 동향과 예측(2019-2031년)
기타 : 동향과 예측(2019-2031년)
제6장 지역 분석
개요
세계의 아르테미시닌 병용요법 시장 : 지역별
제7장 북미의 아르테미시닌 병용요법 시장
개요
북미의 아르테미시닌 병용요법 시장 : 종류별
북미의 아르테미시닌 병용요법 시장 : 용도별
미국의 아르테미시닌 병용요법 시장
멕시코의 아르테미시닌 병용요법 시장
캐나다의 아르테미시닌 병용요법 시장
제8장 유럽의 아르테미시닌 병용요법 시장
개요
유럽의 아르테미시닌 병용요법 시장 : 종류별
유럽의 아르테미시닌 병용요법 시장 : 용도별
독일의 아르테미시닌 병용요법 시장
프랑스의 아르테미시닌 병용요법 시장
스페인아르테미시닌 병용요법 시장
이탈리아의 아르테미시닌 병용요법 시장
영국의 아르테미시닌 병용요법 시장
제9장 아시아태평양의 아르테미시닌 병용요법 시장
개요
아시아태평양의 아르테미시닌 병용요법 시장 : 종류별
아시아태평양의 아르테미시닌 병용요법 시장 : 용도별
일본의 아르테미시닌 병용요법 시장
인도의 아르테미시닌 병용요법 시장
중국의 아르테미시닌 병용요법 시장
한국의 아르테미시닌 병용요법 시장
인도네시아의 아르테미시닌 병용요법 시장
제10장 기타 지역(ROW)의 아르테미시닌 병용요법 시장
개요
ROW의 아르테미시닌 병용요법 시장 : 종류별
ROW의 아르테미시닌 병용요법 시장 : 용도별
중동의 아르테미시닌 병용요법 시장
남미의 아르테미시닌 병용요법 시장
아프리카의 아르테미시닌 병용요법 시장
제11장 경쟁 분석
제품 포트폴리오 분석
운영 통합
Porter's Five Forces 분석
경쟁 기업 간의 경쟁 관계
구매자의 협상력
공급업체의 협상력
대체품의 위협
신규 참여업체의 위협
시장 점유율 분석
제12장 기회와 전략 분석
밸류체인 분석
성장 기회 분석
성장 기회 : 종류별
성장 기회 : 용도별
세계의 아르테미시닌 병용요법 시장 최신 동향
전략 분석
신제품 개발
인증·라이선싱
기업 인수합병(M&A) , 계약, 제휴, 합작투자
제13장 밸류체인 전반에 걸친 주요 기업 개요
경쟁 분석
KPC Pharmaceuticals
Sanofi
Desano Holdings
Mylan
Novartis
제14장 부록
그림목차
표목차
분석 방법
면책사항
저작권
약어와 기술 단위
Lucintel 소개
문의
KSM
영문 목차
영문목차
The future of the global artemisinin combination therapy market looks promising with opportunities in the hospital, clinic markets. The global artemisinin combination therapy market is expected to grow with a CAGR of 8.2% from 2025 to 2031. The major drivers for this market are its demonstrated effectiveness in quickly eliminating parasitemia, alleviating symptoms enhances treatment success rates, and prevent the emergence of drug-resistant malaria strains.
Lucintel forecasts that, within the type category, artemether+lumefantrine is expected to witness the highest growth over the forecast period due to its superior effectiveness and safety in treating uncomplicated malaria.
Within the application category, clinic is expected to witness the higher growth due to treatments are commonly administered in clinics, especially in malaria-endemic regions.
In terms of region, North America will remain the largest region over the forecast period due to the rising number of imported malaria cases and the need for effective treatment options.
Emerging Trends in the Artemisinin Combination Therapy Market
The Artemisinin Combination Therapy market is undergoing rapid transformation, driven by various technological, regulatory, and research developments. These trends reflect the evolving challenges in malaria control, such as drug resistance and affordability, while also highlighting opportunities for innovation and growth in the treatment landscape. The following emerging trends are reshaping the ACT market and pushing it toward more effective, accessible, and sustainable solutions.
Innovation in Fixed-Dose Combinations: Fixed-dose combinations (FDCs) of artemisinin and other antimalarial drugs are gaining momentum due to their ease of use and improved patient adherence. By combining multiple drugs into a single tablet, FDCs reduce the risk of resistance and improve treatment outcomes. Pharmaceutical companies are developing more efficient FDCs with shorter treatment durations, making them highly effective for large-scale malaria control programs. This trend is expected to drive the demand for ACTs, especially in countries with high malaria transmission.
Growing Focus on Resistance Management: As resistance to artemisinin-based therapies becomes a growing concern, researchers are focused on developing new drugs and strategies to overcome this issue. Resistance management initiatives, including new ACT combinations and alternative drugs, are becoming a significant part of the market landscape. This trend is shaping research directions, leading to innovative drug development that can preserve the efficacy of ACT therapies in regions affected by drug-resistant malaria strains, particularly in Southeast Asia and sub-Saharan Africa.
Public-Private Partnerships: The collaboration between governments, international organizations, and private pharmaceutical companies is essential to improving ACT access in malaria-endemic regions. Public-private partnerships (PPPs) are key to ensuring the affordability and availability of ACTs in low-income countries. These partnerships have led to increased production and distribution, as well as the development of novel ACT formulations. Through PPPs, stakeholders aim to increase global supply chains, reduce costs, and expand access to ACT therapies in regions most affected by malaria.
Advances in Delivery Mechanisms: The ACT market is witnessing advancements in drug delivery systems aimed at improving treatment efficacy and patient compliance. Innovations such as controlled-release formulations and injectable ACTs are being explored to provide more efficient dosing regimens. This trend is expected to enhance the effectiveness of ACTs, especially in areas with limited access to healthcare or where oral treatments may not be feasible. These innovations are helping to address the logistical challenges of malaria treatment delivery.
Digital Health Integration: Digital health technologies are being integrated into malaria control programs to improve monitoring, diagnosis, and treatment adherence. Mobile health applications, telemedicine, and data analytics are increasingly used to track the effectiveness of ACT therapies in real time. Digital platforms also support patient education, increasing awareness of malaria prevention and treatment. This trend is reshaping the landscape of ACT distribution and monitoring, enhancing the global response to malaria.
The Artemisinin Combination Therapy (ACT) market is being shaped by a series of emerging trends that reflect the increasing need for innovative solutions in malaria treatment and control. Innovations like fixed-dose combinations, resistance management strategies, and digital health integration are all contributing to more effective, accessible, and sustainable treatment options. Public-private partnerships and advances in drug delivery mechanisms further enhance the scalability of ACT programs globally.
Recent Developments in the Artemisinin Combination Therapy Market
The Artemisinin Combination Therapy (ACT) market is witnessing significant developments that reflect the evolving global response to malaria. These developments are influenced by new therapeutic advancements, international collaborations, and regulatory updates aimed at enhancing the efficacy, affordability, and accessibility of ACTs. The following key developments highlight how the ACT market is transforming to address current and future challenges in malaria treatment.
Introduction of Novel ACT Formulations: Recent developments in the ACT market include the introduction of novel drug formulations that combine artemisinin with new partners, such as pyronaridine and tafenoquine. These new combinations are being developed to combat drug resistance and improve treatment efficacy. For example, the introduction of pyronaridine-artesunate as an alternative to traditional ACTs addresses concerns related to artemisinin resistance in Southeast Asia. These new formulations are expected to provide more durable solutions to malaria treatment.
Expansion of Generic ACT Production: India, China, and several other countries have ramped up the production of generic ACTs, which are helping to make malaria treatment more affordable and accessible in endemic regions. The availability of affordable generic ACTs is critical to the success of malaria control programs in low-income countries. This trend is contributing to the wider distribution of ACTs, especially through government health programs, reducing the economic burden of malaria treatment.
Enhanced Global Collaboration and Funding: Global collaborations and funding from organizations such as the Global Fund to Fight AIDS, Tuberculosis, and Malaria (GFATM) and the World Health Organization (WHO) have increased the availability of ACTs in endemic regions. These collaborations focus on scaling up the distribution of ACTs, improving healthcare infrastructure, and investing in malaria research. Enhanced funding mechanisms and partnerships have played a crucial role in increasing access to ACTs in sub-Saharan Africa and other high-burden regions.
Increased Focus on Malaria Elimination: Several countries have committed to malaria elimination by 2030, and ACT is central to these national strategies. Countries such as China and India are advancing malaria elimination efforts by strengthening ACT supply chains, improving diagnosis and treatment coverage, and integrating ACT use into broader public health programs. These efforts are accelerating the deployment of ACTs in areas with low but persistent malaria transmission, helping to reduce malaria transmission rates and move closer to the goal of global eradication.
Regulatory Advancements in ACT Approvals: Regulatory bodies such as the U.S. FDA and the European Medicines Agency (EMA) have recently approved new ACT combinations and formulations. These regulatory advancements streamline the approval process for ACTs, ensuring quicker access to innovative therapies. With increasing approval of new combinations and alternative drugs, the global market for ACTs is diversifying, offering more options for malaria treatment, especially in areas facing artemisinin resistance.
Recent developments in the Artemisinin Combination Therapy (ACT) market are focused on enhancing drug efficacy, accessibility, and addressing challenges like drug resistance. The introduction of novel formulations, increased generic production, and global collaborations has expanded the availability of ACTs in malaria-endemic regions. Efforts toward malaria eradication and advancements in regulatory approvals are reshaping the market, while innovations in ACT formulations are improving treatment outcomes.
Strategic Growth Opportunities in the Artemisinin Combination Therapy Market
The Artemisinin Combination Therapy (ACT) market is poised for growth, driven by strategic opportunities across various applications. These growth opportunities are linked to innovations in drug formulations, global health initiatives, and the expanding focus on malaria eradication. The following are key growth opportunities by application in the ACT market, each playing a critical role in shaping the future of malaria control and treatment.
Strengthening Malaria Control Programs: A significant growth opportunity lies in strengthening national malaria control programs (NMCPs) in malaria-endemic countries. ACTs play a central role in these programs, where governments are investing in mass drug administration campaigns, integrated vector management, and surveillance systems. Expanding access to ACTs through government-run distribution programs is critical to achieving the World Health Organization's global malaria targets, particularly in regions such as sub-Saharan Africa.
Pediatric Malaria Treatment: Pediatric malaria treatment represents a key growth opportunity, with increasing focus on formulating ACTs that are more suitable for children. Efforts are being made to improve the palatability, dosage, and safety of ACTs for pediatric patients, as this group faces higher mortality rates from malaria. The development of pediatric-friendly ACT formulations and combination therapies is expected to drive market growth in countries with high childhood malaria burden.
Scaling Up Preventative Malaria Treatment: Preventative malaria treatment strategies, such as seasonal malaria chemoprevention (SMC), are gaining momentum. ACTs are integral to these efforts, which involve administering ACTs to individuals in malaria-endemic regions during peak transmission seasons. The scalability of these preventive programs offers significant growth potential for the ACT market, especially in areas where seasonal malaria transmission is a major concern.
Investment in Malaria Vaccine Programs: While vaccines are not yet a complete solution, their integration with ACT treatments presents a unique growth opportunity. Malaria vaccine initiatives, such as the RTS,S/AS01 vaccine, are complementing ACTs in regions with high malaria transmission. The convergence of vaccines and ACTs creates synergies that could improve malaria control, expanding the market for ACTs and providing new channels for distribution and application.
Expansion of Malaria Research and Development: The ongoing research into drug-resistant malaria and new therapies presents an opportunity for growth. Investment in R&D for novel ACTs, combination therapies, and alternative treatment regimens is expected to open new market avenues. As new formulations and treatments are developed, these will complement the current ACT landscape and further drive demand.
These applications collectively contribute to a comprehensive approach to malaria control, opening up avenues for growth and reinforcing global efforts to combat malaria. As these opportunities are harnessed, the ACT market is set to become a central pillar of malaria eradication initiatives.
Artemisinin Combination Therapy Market Driver and Challenges
The Artemisinin Combination Therapy (ACT) market is influenced by various drivers and challenges. These include technological advancements in drug development, economic considerations, and regulatory frameworks. On the one hand, advancements in ACT formulations and collaborations in global health have led to increased market demand. On the other hand, challenges like drug resistance and affordability constraints affect its growth potential. Understanding these dynamics is essential to navigating the market's evolution.
The factors responsible for driving the Artemisinin Combination Therapy market include:
1. Increase in Malaria Cases: The rising incidence of malaria, particularly in sub-Saharan Africa and Southeast Asia, drives the demand for ACTs. With approximately 200 million cases globally, ACTs are critical for controlling outbreaks and improving public health outcomes. The growth in malaria cases in certain regions underscores the need for effective treatment options, supporting the market for ACTs.
2. Government and NGO Support: Governments and international organizations play a pivotal role in funding ACT distribution programs. Agencies like the Global Fund, WHO, and various national health ministries are investing heavily in malaria eradication, increasing the accessibility and availability of ACTs worldwide. This financial and institutional support fosters market expansion, especially in high-burden regions.
3. Advancements in ACT Formulations: Research and development into novel ACT formulations, such as fixed-dose combinations and improved drug delivery mechanisms, are significant drivers. These innovations improve treatment outcomes, reduce side effects, and enhance patient compliance, which makes ACTs more attractive for malaria-endemic countries, boosting market demand.
4. Cost Reduction and Generic Production: The growing production of generic ACTs, particularly by Indian and Chinese pharmaceutical companies, has lowered the cost of malaria treatment. These affordable options are critical for low-income countries, increasing the penetration of ACTs in endemic regions and driving overall market growth.
5. Focus on Malaria Eradication: The global push towards malaria elimination by 2030 provides a strong growth driver for the ACT market. National strategies focused on malaria eradication rely heavily on effective treatment options, with ACTs playing a central role. This focus on eradication ensures sustained demand and strategic investments in the ACT market.
Challenges in the Artemisinin Combination Therapy market are:
1. Drug Resistance: Artemisinin resistance, particularly in Southeast Asia, poses a significant threat to the efficacy of ACTs. The emergence of resistant strains necessitates the development of new ACT combinations and alternatives to maintain effectiveness. Resistance challenges may hinder the widespread use of current ACTs if not addressed.
2. Affordability and Access: While generics have lowered prices, the affordability of ACTs remains a challenge in low-income regions. Issues related to distribution, healthcare infrastructure, and financial barriers affect access to ACTs in the most vulnerable populations, limiting their impact on malaria control.
3. Supply Chain and Distribution Constraints: The global supply chain for ACTs faces logistical challenges, including the timely delivery of drugs to remote and hard-to-reach areas. Inefficient distribution systems and stock outs continue to be barriers, hindering the consistent availability of ACTs when and where they are most needed.
The drivers and challenges in the ACT market are interrelated. While increasing malaria cases and advancements in drug formulations fuel growth, challenges such as resistance and access barriers require attention. Strategic investments and collaborations will be crucial to overcoming these hurdles and ensuring the continued success of ACTs in global malaria control efforts.
List of Artemisinin Combination Therapy Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies artemisinin combination therapy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the artemisinin combination therapy companies profiled in this report include-
KPC Pharmaceuticals
Sanofi
Desano Holdings
Mylan
Novartis
Artemisinin Combination Therapy Market by Segment
The study includes a forecast for the global artemisinin combination therapy market by type, application, and region.
Artemisinin Combination Therapy Market by Type [Value from 2019 to 2031]:
Artemether+Lumefantrine
Artesunate+Amodiaquine
Dihydroartemisinin+Piperaquine
Artesunate+Mefloquine
Artesunate+Sulfadoxine-Pyrimethamine
Pyronaridine-Artesunate
Others
Artemisinin Combination Therapy Market by Application [Value from 2019 to 2031]:
Hospital
Clinic
Other
Artemisinin Combination Therapy Market by Region [Value from 2019 to 2031]:
North America
Europe
Asia Pacific
The Rest of the World
Country Wise Outlook for the Artemisinin Combination Therapy Market
Artemisinin Combination Therapy (ACT) is the gold-standard treatment for malaria, especially in areas with widespread drug-resistant malaria strains. The market for ACT is growing due to rising malaria incidences, particularly in developing countries, but also due to advancements in drug formulations and production methods. Emerging markets, such as China and India, play a critical role in shaping this growth. Meanwhile, developed countries like the United States, Germany, and Japan are focused on supporting global health initiatives and investing in innovative ACT research. Here we explore the key developments, trends, growth opportunities, and challenges in the ACT market in the United States, China, Germany, India, and Japan.
United States: The United States has seen a continued focus on supporting global malaria eradication efforts. A key development in the ACT market is the government's investment in research and development of new drug formulations. The U.S. is also a major supplier of ACT medicines through organizations like the U.S. Agency for International Development (USAID). However, domestically, malaria cases are relatively low, so ACT demand is mainly driven by U.S.-funded international programs. The U.S. is increasingly involved in the deployment of newer ACT formulations in sub-Saharan Africa and Southeast Asia, with an emphasis on cost-effective and efficient therapies.
China: China remains a critical player in the global ACT market. The country has significantly reduced its malaria burden, but it continues to invest heavily in malaria research. China's advancements in manufacturing and producing artemisinin-based therapies have led to cost reductions, making ACT more accessible across Southeast Asia and sub-Saharan Africa. In addition, Chinese companies are increasingly involved in clinical trials to develop next-generation ACT treatments. The government is also focusing on integrating ACT with other public health programs to eradicate malaria by 2030, positioning China as a key hub for innovation and supply in the ACT market.
Germany: Germany's role in the ACT market is largely driven by its commitment to international development and malaria eradication. The country supports the global roll-out of ACT through collaborations with international organizations, including the World Health Organization (WHO). German pharmaceutical companies are also active in improving the efficacy and affordability of ACT, with investments in the development of fixed-dose combination therapies (FDCs). Furthermore, Germany is a key player in malaria research, with its scientific community focusing on the development of new ACT formulations to combat emerging resistance.
India: India, with its large population and high malaria burden, is both a producer and a consumer of ACT. The country has focused on increasing access to ACT for its domestic population, which is critical for controlling malaria transmission. Indian pharmaceutical companies, including Cipla and Dr. Reddy's Laboratories, play a key role in producing affordable generic ACTs, which are distributed through government programs. India is also engaged in developing more efficient and robust ACT formulations to combat drug resistance, with ongoing efforts to improve drug delivery and minimize side effects in the population.
Japan: Japan's involvement in the ACT market is primarily through international development and research. While domestic malaria cases are extremely low, Japan is heavily invested in global malaria eradication efforts. Japan's pharmaceutical industry has made significant contributions to the ACT market through collaborations and research on more effective therapies. Moreover, Japan supports malaria control through organizations like the Japan International Cooperation Agency (JICA), which is focused on funding ACT distribution in malaria-endemic regions, particularly in Southeast Asia and Africa. Japan also plays a crucial role in improving malaria diagnostics and treatment protocols.
Features of the Global Artemisinin Combination Therapy Market
Market Size Estimates: Artemisinin combination therapy market size estimation in terms of value ($M).
Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
Segmentation Analysis: Artemisinin combination therapy market size by type, application, and region in terms of value ($M).
Regional Analysis: Artemisinin combination therapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the artemisinin combination therapy market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the artemisinin combination therapy market.
Analysis of competitive intensity of the industry based on Porter's Five Forces model.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the artemisinin combination therapy market by type (artemether+lumefantrine, artesunate+amodiaquine, dihydroartemisinin+piperaquine, artesunate+mefloquine, artesunate+sulfadoxine-pyrimethamine, pyronaridine-artesunate, and others), application (hospital, clinic, and other), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
Table of Contents
1. Executive Summary
2. Market Overview
2.1 Background and Classifications
2.2 Supply Chain
3. Market Trends & Forecast Analysis
3.2 Industry Drivers and Challenges
3.3 PESTLE Analysis
3.4 Patent Analysis
3.5 Regulatory Environment
4. Global Artemisinin Combination Therapy Market by Type
4.1 Overview
4.2 Attractiveness Analysis by Type
4.3 Artemether+Lumefantrine: Trends and Forecast (2019-2031)
4.4 Artesunate+Amodiaquine: Trends and Forecast (2019-2031)
4.5 Dihydroartemisinin+Piperaquine: Trends and Forecast (2019-2031)
4.6 Artesunate+Mefloquine: Trends and Forecast (2019-2031)
4.7 Artesunate+Sulfadoxine-Pyrimethamine: Trends and Forecast (2019-2031)
4.8 Pyronaridine-Artesunate: Trends and Forecast (2019-2031)
4.9 Others: Trends and Forecast (2019-2031)
5. Global Artemisinin Combination Therapy Market by Application
5.1 Overview
5.2 Attractiveness Analysis by Application
5.3 Hospital: Trends and Forecast (2019-2031)
5.4 Clinic: Trends and Forecast (2019-2031)
5.5 Other: Trends and Forecast (2019-2031)
6. Regional Analysis
6.1 Overview
6.2 Global Artemisinin Combination Therapy Market by Region
7. North American Artemisinin Combination Therapy Market
7.1 Overview
7.2 North American Artemisinin Combination Therapy Market by Type
7.3 North American Artemisinin Combination Therapy Market by Application
7.4 United States Artemisinin Combination Therapy Market
